SR ONE
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
SR ONE
Social Links:
Industry:
Finance Financial Services Health Care Venture Capital
Founded:
1985-01-01
Status:
Active
Contact:
(610) 567-1000
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Content Delivery Network LetsEncrypt Amazon SSL By Default HSTS Nginx
Similar Organizations
Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
100x Ventures
100x Ventures is the corporate venture capital arm of 100x Group
Caffeinated Capital
Caffeinated Capital is a technology venture capital firm that partners with founders at the inception stage.
Foundation Capital
Foundation Capital is a venture capital firm made up of former entrepreneurs and helps companies and businesses grow.
General Catalyst
General Catalyst is a venture capital firm that provides early-stage and growth equity investments.
Highland Capital Partners
Highland Capital Partners is a venture capital firm that offers seed, early, and growth-stage funding solutions.
Nexus Venture Partners
Nexus Venture Partners is a venture capital firm established by ex-entrepreneurs in enterprise technology and consumer internet.
Pfizer Venture Investments
Pfizer Venture Investments is a venture capital firm.
Union Square Ventures
Union Square Ventures is a venture capital firm that focuses on early-stage, growth-capital, late-stage, and startup financing.
Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-07-17 | Renalys Pharma | SR One investment in Series A - Renalys Pharma | 6 B JPY |
| 2024-07-16 | Asceneuron | SR One investment in Series C - Asceneuron | 100 M USD |
| 2024-06-27 | Kala Pharmaceuticals | SR One investment in Post-IPO Equity - Kala Pharmaceuticals | 12.5 M USD |
| 2024-05-07 | Zenas BioPharma | SR One investment in Series C - Zenas BioPharma | 200 M USD |
| 2024-03-25 | Nkarta Therapeutics | SR One investment in Post-IPO Equity - Nkarta Therapeutics | 240 M USD |
| 2024-03-14 | MISSION Therapeutics | SR One investment in Series D - MISSION Therapeutics | 25.2 M GBP |
| 2024-03-06 | Alumis | SR One investment in Series C - Alumis | 259 M USD |
| 2024-02-13 | CRISPR Therapeutics | SR One investment in Post-IPO Equity - CRISPR Therapeutics | 280 M USD |
| 2023-12-05 | Odyssey Therapeutics | SR One investment in Series C - Odyssey Therapeutics | 101 M USD |
| 2023-09-27 | Avalyn Pharma | SR One investment in Series C - Avalyn Pharma | 175 M USD |
More informations about "SR One"
SR One - Crunchbase Investor Profile & Investments
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested …See details»
SR One Capital Management - LinkedIn
SR One Capital Management is a transatlantic biotech venture capital firm that seeks to partner with who we believe to be top entrepreneurs, scientists and investment partners in an effort to ...See details»
Chris Chai - SR One
Biotech companies go through numerous transformative events including pre-clinical to clinical, privately held to publicly traded, and importantly R&D to a commercial organization. We are …See details»
Matthew R. Patterson - SR One
He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and …See details»
SR One - Investments, Portfolio & Company Exits - Crunchbase
SR One 's most notable exits include Arcellx, Lexicon Pharmaceuticals, and Zenas BioPharma. Which industries has this organization had the most exits in? Show . Arcellx Arcellx is a clinical …See details»
List of top SR One Portfolio Companies - Crunchbase
Jan 5, 2008 SR One is the corporate venture capital arm of GlaxoSmithKline. This list of organizations invested in by SR One provides data on their funding history, investment …See details»
Leaning in to non-linear paths — how SR One is ... - BioCentury
Dec 14, 2023 With about $1.5 billion in assets under management, and having closed its second fund this year at $600 million, SR One is sailing free from the mothership GSK that it left in …See details»
SR One closes second venture fund at $600m
Apr 6, 2023 SR One, which was spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent venture capital business, recently announced the close of its second fund at over US$600m. With Fund II, the investment firm …See details»
SR One Capital Management investment portfolio
Jun 28, 2024 SR One Capital Management's latest investment was on 01-Nov-2024 in Phylaxis Biosciences, a company within the Drug Discovery industry. Data Transparency. Meet our data hygiene team. Discover how our experts …See details»
Briana Wilson - SR One
Briana joined SR One in 2023 and is based in the San Francisco Bay Area office. Briana provides administrative support for various team members within the organization in addition to supporting Frances in event planning and vendor …See details»
SR One breaks off from GlaxoSmithKline, banks $500M fund
Nov 19, 2020 SR One’s new fund comes as seemingly everybody in the VC world is raising life sciences fund. Just last month, Canaan Partners raised $800 million in its 12th fund to back …See details»
SR One - Funding, Financials, Valuation & Investors - Crunchbase
SR One has raised a total of $600M in a single venture fund, SR One Fund II. This fund was announced on Mar 27, 2023 and raised a total of . obfuscated. obfuscated. Announced Date . …See details»
SR One Completes Spin-out from GSK and Closes First Fund at
Nov 19, 2020 SR One Chief Executive Officer, Simeon George, with the firm since 2007, said, “Our spin-out from GSK and successful raise of a new independent fund provide a foundation …See details»
SR One Completes Spin-out from GSK and Closes First Fund at …
Nov 19, 2020 SR One Chief Executive Officer, Simeon George, with the firm since 2007, said, “Our spin-out from GSK and successful raise of a new independent fund provide a foundation …See details»
Simeon George, MD - SR One
Simeon is CEO and Managing Partner of SR One. Simeon co-founded SR One Capital Management following its spin-out from GSK in 2020. Previously, he worked in management …See details»
After an ‘amazing year,’ SR One raises $600M to fuel more drug …
Mar 27, 2023 Dive Brief: SR One, the former venture arm of GSK, has raised its second fund since spinning out of the pharmaceutical company, announcing Monday a new $600 million …See details»
Simeon George - Chief Executive Officer @ SR One - Crunchbase
Simeon joined SR One in 2007 and leads SR Ones investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at …See details»
VC firm SR One completes GSK spin-out, raising $500m
Nov 19, 2020 Trans-Atlantic biotech venture capital firm SR One has completed its spin-out from GlaxoSmithKline and closed its first fund with $500m in its coffers. The VC built itself a …See details»
SR One - Contacts, Employees, Board Members, Advisors
SR One has 10 current employee profiles, including President Jens Eckstein. Contacts. Edit Contacts Section. Job Department. Protected Content. Principal. Director. 1 phone number …See details»